Equity Overview
Price & Market Data
Price: $1.04
Daily Change: +$0.0852 / 8.19%
Range: $0.90 - $1.14
Market Cap: $3,062,155
Volume: 221,513
Performance Metrics
1 Week: 26.81%
1 Month: -36.20%
3 Months: -78.24%
6 Months: -85.75%
1 Year: -99.79%
YTD: -82.72%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.